Testing Zanzalintinib for Advanced Bone Sarcomas
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of bone sarcoma that has spread or cannot be removed by surgery.
- You have had at least one prior treatment for your cancer, but no more than two.
- You have not taken a similar drug (like cabozantinib, regorafenib, or pazopanib) before.
- You are generally able to care for yourself (ECOG score 0-2) and weigh at least 40 kg (88 lbs).
- Your kidneys, liver, and blood counts are within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
Hear when a new Bone Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.